Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Axonics Modulation Technologies Inc (AXNX) USD0.0001

Sell:$19.55 Buy:$19.57 Change: $1.24 (5.96%)
NASDAQ:0.72%
Market closed |  Prices as at close on 22 October 2019 | Switch to live prices |
Sell:$19.55
Buy:$19.57
Change: $1.24 (5.96%)
Market closed |  Prices as at close on 22 October 2019 | Switch to live prices |
Sell:$19.55
Buy:$19.57
Change: $1.24 (5.96%)
Market closed |  Prices as at close on 22 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Axonics Modulation Technologies, Inc. is a medical technology company. The Company is focused on the design, development, and commercialization of sacral neuromodulation (SNM) solutions. SNM therapy is primarily used to treat patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). Its rechargeable SNM system (r-SNM System) delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR. It has two clinical studies relating to its r-SNM System: a European study, RELAX-OAB, and a United States pivotal study, ARTISAN-SNM. SNM therapy consists of two phases: an evaluation period, also called the external trial period, which typically lasts a few days to a few weeks, and a permanent implant for those patients who experience a successful external trial period.

Contact details

Address:
26 Technology Dr
IRVINE
92618-2380
United States
Telephone:
+1 (949) 3966322
Website:
https://www.axonicsmodulation.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
AXNX
ISIN:
US05465P1012
Market cap:
$593.60 million
Shares in issue:
28.52 million
Sector:
Health Care Equipment
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Raphael Wisniewski
    Independent Chairman of the Board
  • Dan Dearen
    President, Chief Financial Officer
  • Raymond Cohen
    Chief Executive Officer, Director
  • Rinda Sama
    Chief Operating Officer
  • Michael Williamson
    Senior Vice President, General Counsel
  • Guangqiang Jiang
    Chief Technology Officer
  • John Woock
    Chief Marketing Officer
  • Emilie Finiels
    Vice President - Business Development
  • Alfred Ford
    Chief Commercial Officer
  • Prabodh Mathur
    Chief Product Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.